A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).
Alireza Shamaei-Tousi, PhD
Advertisement
Shamaei-Tousi is a principal clinical scientist at Debiopharm.
Articles by Alireza Shamaei-Tousi, PhD
Advertisement
Latest Updated Articles
Early-Stage Antibiotic for Bone and Joint Infections Comparable to Standard of Care TherapyPublished: December 9th 2024 | Updated:
Advertisement
Advertisement
